Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,673–1,680 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Ernexa Therapeutics Inc. IRX-2 (CIN-201) Cervical Squamous Intraepithelial Neoplasia 3 Phase 2 Trial Discontinued Subcutaneous injection Oncology
Ernexa Therapeutics Inc. IRX-2 - (INSPIRE) Head and neck squamous cell cancer Phase 2b Trial Discontinued subcutaneous injection Oncology
Ernexa Therapeutics Inc. IRX-2 and KEYTRUDA (pembrolizumab) - (BR-202) Breast Cancer Phase 2 Trial Discontinued IRX-2: subcutaneous KEYTRUDA pembrolizumab: intravenous Oncology
Erytech Pharma S.A. GRASPA (Eryaspase) Acute lymphoblastic leukemia (ALL) BLA Filing Intravenous Oncology
Erytech Pharma S.A. Eryaspase - (Trybeca-1) Pancreatic cancer Phase 3 Intravenous Oncology
Erytech Pharma S.A. Hydro-Lido Hemorrhoids Phase 2a Topical N/A
Erytech Pharma S.A. Hydro-Lido Hemorrhoids Phase 2a Topical N/A
Erytech Pharma S.A. GRASPA (Eryaspase) with gemcitabine and carboplatin chemotherapy - (TRYbeCA-2) Triple-Negative Breast Cancer (TNBC) Phase 2/3 Intravenous Oncology